Helps diagnose suspected or known acute opioid overdosage. ANDA 214785, held by Baxter Healthcare. Naloxone Hydrochloride.
As of Nov 22, 2026, ANDA 214785 (Naloxone Hydrochloride), held by Baxter Healthcare, was first approved by FDA on Jan 29, 2021, with 1 approved supplement and 0 published complete response letters.
INDICATIONS AND USAGE Naloxone hydrochloride injection is indicated for the complete or partial reversal of opioid depression, including respiratory depression, induced by natural and synthetic opioids, including propoxyphene, methadone and certain mixed agonist-antagonist analgesics: nalbuphine, pentazocine, butorphanol, and cyclazocine. Naloxone hydrochloride injection is also indicated for diagnosis of suspected or known acute opioid overdosage. Naloxone hydrochloride injection may be useful as an adjunctive agent to increase blood pressure in the management of septic shock (see CLINICAL PHARMACOLOGY; Adjunctive Use in Septic Shock ).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 29, 2021 | Original application | Approved | None posted |
| Naloxone Hydrochloride0.4MG/ML · injectable;injection | Naloxone Hydrochloride | Rx |
| Naloxone Hydrochloride1MG/ML · injectable;injection | Naloxone Hydrochloride | Rx |
| Aug 28, 2024 | Supplement 4Labeling · Standard review | Approved | None posted |
| Jan 29, 2021 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters